Image

Global Human Insulin Drugs and Delivery Devices Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Human Insulin Drugs and Delivery Devices Market, By Product (Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices), Drug (Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics), Delivery Device (Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles), Application (Type I Diabetes, Type II Diabetes), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Human Insulin Drugs and Delivery Devices Market

Human Insulin Drugs and Delivery Devices Market Analysis and Size

In recent years, the market of human insulin drugs and delivery devices is anticipated to grow rapidly during the forecast period. Diabetes is a condition caused by poor lifestyle choices. With the rise in global population, the disease's prevalence has skyrocketed. Insulin is required by around 100 million people worldwide, including all patients with Type 1 diabetes and between 10% and 25% of people with Type 2 diabetes. Hence, the demand for human insulin drugs and delivery devices is increasing in the market.

Data Bridge Market Research analyses that the human insulin drugs and delivery devices market was valued at USD 42.85 billion in 2021 and is expected to reach USD 80.79 billion by 2029, registering a CAGR of 8.25% during the forecast period of 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Human Insulin Drugs and Delivery Devices Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product (Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices), Drug (Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics), Delivery Device (Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles), Application (Type I Diabetes, Type II Diabetes), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Biocon (India), Boehringer Ingelheim International GmbH. (Germany), Medtronic (Ireland), Ypsomed AG (Switzerland), Julphar (UAE), Albireo Pharma, Inc. (U.S.). CeQur Simplicity (Switzerland), BD (U.S.), B. Braun SE (Germany), Novo Nordisk A/S (Denmark), WOCKHARDT (India)   

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment in the development of advanced technologies
  • Surging drug approvals and launches

Market Definition

Insulin is a protein hormone that assists people whose bodies cannot make enough insulin control their blood sugar levels. Insulin increases glucose absorption into fatty tissues and muscles, lowering blood glucose levels. It can be injected into the buttocks, the back of the arms, the abdomen, or the legs. Furthermore, insulin not only aids in the management of diabetes but also aids in the treatment of acute complications such as hyperosmolar hyperglycemia and diabetic ketoacidosis. Insulin syringes, insulin pumps, insulin pens, insulin inhalers, and insulin jet injectors are some of the devices that help deliver insulin to the patient's body.

Human Insulin Drugs and Delivery Devices Market Dynamics

Drivers

  • Increasing prevalence of diabetes

The rising prevalence of diabetes, mainly type 2 diabetes, is a primary driver of the growth of human insulin drugs and delivery devices. Changing dietary patterns and sedentary lifestyle are the factors that will influence the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of human insulin drugs and delivery devices market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the human insulin drugs and delivery devices market. Additionally, high disposable income and favorable reimbursement scenario will expand human insulin drugs and delivery devices market. Along with this, the rising geriatric population and advancement in insulin device design will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the growth of human insulin drugs and delivery devices. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of human insulin drugs and delivery devices during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the manufacturing of delivery devices will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market of human insulin drugs and delivery devices. Additionally, strict regulations and reforms for the approval of products and the dearth of awareness among people will act as restrain and further impede the market growth rate during the forecast period of 2022-2029.

This human insulin drugs and delivery devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human insulin drugs and delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Human insulin drugs and delivery devices market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Human Insulin Drugs and Delivery Devices Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.

The supply chain for the raw materials needed to make human insulin medicines and delivery devices has been interrupted in numerous countries as a result of COVID-19. Furthermore, the market for human insulin medications and delivery devices is shrinking as a result of the outbreak, as makers of these drugs and devices have restricted production. As a result, COVID 19 is projected to significantly influence the market for human insulin medicines and delivery systems.

Global Human Insulin Drugs and Delivery Devices Market Scope

The human insulin drugs and delivery devices market is segmented on the basis of product, application, drug, delivery device, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Human Insulin (HI) Drugs
  • Human Insulin (HI) Delivery Devices

Drug

  • Insulin Analogs and Biosimilar
  • Long-Acting Biosimilar
  • Rapid-Acting Biosimilar
  • Premixed Biosimilar
  • Human Insulin Biologics
  • Short-Acting Biologics
  • Intermediate-Acting Biologics
  • Premixed Biologics

Application

  • Type I Diabetes
  • Type II Diabetes

Delivery Device

  • Syringes
  • Pens
  • Disposable Pens
  • Reusable Pens
  • Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Human Insulin Drugs and Delivery Devices Market Regional Analysis/Insights

The Human insulin drugs and delivery devices market is analyzed and market size insights and trends are provided by country, product, application, drug, delivery device, end-users and distribution channel as referenced above.

The countries covered in the Human insulin drugs and delivery devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America and Europe dominate the human insulin drugs and delivery devices market because of the growing prevalence of diabetes in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Human Insulin Drugs and Delivery Devices Market Share Analysis

The human insulin drugs and delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human insulin drugs and delivery devices market.

Some of the major players operating in the human insulin drugs and delivery devices market are:

  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Lilly (U.S.)
  • Merck & Co., Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Biocon (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Medtronic (Ireland)
  • Ypsomed AG (Switzerland)
  • Julphar (UAE)
  • Albireo Pharma, Inc. (U.S.)
  • CeQur Simplicity (Switzerland)
  • BD (U.S.)
  • B. Braun SE (Germany)
  • Novo Nordisk A/S (Denmark)
  • WOCKHARDT (India)    

Research Methodology: Global Human Insulin Drugs and Delivery Devices Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-
Why Choose Us


Frequently Asked Questions

The market value for human insulin drugs and delivery devices market in 2021 is USD 42.85 billion.
The human insulin drugs and delivery devices market is to grow at a CAGR of 8.25% during the forecast period of 2022 to 2029.
North America and Europe dominate the human insulin drugs and delivery devices market because of the growing prevalence of diabetes in this region. Additionally, the growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to a number of population and rising healthcare expenditure in this region.